pentamidine has been researched along with Leishmaniasis, Visceral in 111 studies
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.
Leishmaniasis, Visceral: A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twelve cases of diabetes mellitus following pentamidine isethionate ( Lomidine ) treatment for antimonial -resistant cases of kala-azar are reported." | 7.67 | Pentamidine-induced diabetes mellitus. ( Jha, TK; Sharma, VK, 1984) |
| "We report a retrospective and descriptive study of four immunocompromised patients (three with HIV-1 and one with idiopathic CD4+-lymphopenia) with relapsing visceral leishmaniasis seen at the Hospital for Tropical Diseases, London, in whom pentamidine was used as secondary prophylaxis to prevent relapse." | 3.75 | Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases. ( Lockwood, DN; Patel, TA, 2009) |
| "Twelve cases of diabetes mellitus following pentamidine isethionate ( Lomidine ) treatment for antimonial -resistant cases of kala-azar are reported." | 3.67 | Pentamidine-induced diabetes mellitus. ( Jha, TK; Sharma, VK, 1984) |
| "Metronidazole has been claimed in several earlier reports to be active in human cases of leishmaniasis and trypanosomiasis." | 3.66 | Inefficacy of metronidazole in experimental infections of Leishmania donovani, L. mexicana, and Trypanosoma brucei brucei. ( Keithly, JS; Langreth, SG, 1983) |
| " Severe and irreversible adverse effect appear to be rare." | 2.72 | Efficacy and safety of pentamidine isethionate for tegumentary and visceral human leishmaniasis: a systematic review. ( Bartoloni, A; Lagi, F; Piccica, M; Zammarchi, L, 2021) |
| "A randomized clinical trial of low dosage combination of pentamidine and allopurinol was carried out with objectives to assess the efficacy and toxicity as compared to full dosage of pentamidine in antimony unresponsive visceral leishmaniasis (VL) patients." | 2.70 | A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. ( Das, VN; Gupta, AK; Kar, SK; Lal, CS; Ranjan, A; Siddiqui, NA; Sinha, AN; Verma, N, 2001) |
| "We report a 46-year-old patient with acquired immune deficiency syndrome who, 7 months after diagnosis of VL, developed PKDL and uveal leishmaniasis following HAART-induced immune recovery." | 2.44 | Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. ( Acquaviva, V; Antinori, S; Bestetti, G; Corbellino, M; Foschi, A; Longhi, E; Meroni, L; Parravicini, C; Piolini, R; Trovati, S, 2007) |
| "Major therapeutic obstacles in the treatment of visceral leishmaniasis (VL) include the alarming increase in antimonial unresponsiveness especially in Bihar, India and relapses in HIV-Leishmania co-infected patients." | 2.43 | Visceral leishmaniasis - current therapeutic modalities. ( Chatterjee, M; Sundar, S, 2006) |
| "Visceral leishmaniasis is caused by hemoflagellate protozoa which are obligatory parasites of the mononuclear phagocyte system." | 2.39 | [Importance of drug carriers in the treatment of visceral leishmaniasis]. ( Bories, C; Boulard, Y; Deniau, M; Durand, R; Fusai, T; Houin, R; Paul, M; Rivollet, D, 1995) |
| "The need for drug combinations to treat visceral leishmaniasis (VL) arose because of resistance to antimonials, the toxicity of current treatments and the length of the course of therapy." | 1.37 | Investigation into in vitro anti-leishmanial combinations of calcium channel blockers and current anti-leishmanial drugs. ( Reimão, JQ; Tempone, AG, 2011) |
| " Furthermore, these compounds distributed to target tissues (liver and spleen) and had a moderate oral bioavailability (up to 25%), a large volume of distribution, and an elimination half-life ranging from 1 to 2 days in mice." | 1.36 | Novel arylimidamides for treatment of visceral leishmaniasis. ( Boykin, DW; Hall, JE; Kyle, DE; Liu, Q; Madhubala, R; Mandal, S; Munde, M; Pandharkar, T; Parman, T; Riccio, E; Srivastava, A; Stephens, CE; Sweat, JM; Tidwell, RR; Wang, MZ; Werbovetz, KA; Wilson, WD; Zhu, X, 2010) |
| "Pentamidine treatment has been used successfully to establish immune cellular responses in recovered dogs." | 1.32 | Western blot analysis of Leishmania infantum antigens using sera from pentamidine-treated dogs. ( Lasri, S; Natami, A; Rhalem, A; Sahibi, H, 2003) |
| "Kala-azar, or visceral leishmaniasis, is a hemoparasitic disease caused by Leishmania donovani." | 1.31 | Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable anti-leishmanial drugs: a community-based study. ( Dwivedi, SN; Kumar, J; Singh, R, 2000) |
| "Pentamidine was the first drug to be used and cured 99% of these refractory patients, but over time even with double the amount of initial doses, it cures only 69-78% patients now and its use has largely been abandoned in India." | 1.31 | Drug resistance in Indian visceral leishmaniasis. ( Sundar, S, 2001) |
| " It was not possible to obtain the ED90 for free pentamidine because the dose-response curve reached a plateau near 60% of parasite suppression." | 1.30 | Activity of pentamidine-loaded methacrylate nanoparticles against Leishmania infantum in a mouse model. ( Astier, A; Deniau, M; Durand, R; Houin, R; Paul, M; Rivollet, D, 1997) |
| " The three most active salts were selected: [PtIVBr6]H2 (pentamidine); [PtIVBr6]H2 (stilbamidine), and [PtIVCl6]H2 (2-piperazinyl(1) ethyl amine), which induced growth-inhibition rates of more than 50% at 24 h of treatment and at the maximum dosage tested." | 1.30 | In vitro and in vivo activity of two Pt(IV) salts against leishmania donovani. ( Craciunescu, D; Mesa-Valle, CM; Moraleda-Lindez, V; Osuna, A; Rodriguez-Cabezas, MN; Sanchez-Moreno, M, 1998) |
| "Frequent relapses after treatment for visceral leishmaniasis and apparent parasitological cure is not commonly reported." | 1.29 | Problems in the treatment of kala-azar: case report. ( Kirigi, G; Mbugua, J; Muigai, R; Nyakundi, PM; Rashid, JR; Wasunna, KM; Were, JB, 1995) |
| "Visceral leishmaniasis was detected incidentally in a patient with acute lymphoblastic leukaemia in remission, during maintenance therapy." | 1.29 | Asymptomatic visceral leishmaniasis in a child with acute lymphoblastic leukaemia. ( Choudhry, VP; Kapila, K; Mehrotra, R; Saraya, AK; Saxena, R, 1995) |
| "The WHO recommendations treating visceral leishmaniasis with prolonged administration of Glucantime may prevent relapses." | 1.29 | [Resistance of Leishmania infantum to Glucantime: risk factors and therapeutic management]. ( Dumon, H; Gambarelli, F; Garnier, JM; Kaplanski, S; Piarroux, R; Unal, D, 1996) |
| "The efficiency of antileishmanial agents may be enhanced by improving their bioavailability with a colloidal drug carrier." | 1.29 | Action of pentamidine-bound nanoparticles against Leishmania on an in vivo model. ( Astier, A; Bories, C; Deniau, M; Durand, R; Fusai, T; Houin, R; Paul, M; Rivollet, D, 1994) |
| "Visceral leishmaniasis is an important public health problem in Libya, but its exact prevalence is not known." | 1.28 | Visceral leishmaniasis in Libya--review of 21 cases. ( el-Mauhoub, MM; Mehabresh, MI, 1992) |
| "Pentamidine isethionate was found to be a very effective therapeutic agent in the treatment of pentavalent antimonial-resistant cases of kala-azar." | 1.27 | Evaluation of diamidine compound (pentamidine isethionate) in the treatment resistant cases of kala-azar occurring in North Bihar, India. ( Jha, TK, 1983) |
| " If activity in this model is comparable to activity in humans, these results suggest that a single injection of a preparation consisting of ghosts of a patient's own red cells and the amount of pentamidine in one standard dosage (4 mg/kg) would eliminate 80%-100% of L." | 1.27 | Activity of pentamidine-containing human red cell ghosts against visceral leishmaniasis in the hamster. ( Berman, JD; Gallalee, JV; Hockmeyer, WD; Williams, JS, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (22.52) | 18.7374 |
| 1990's | 47 (42.34) | 18.2507 |
| 2000's | 17 (15.32) | 29.6817 |
| 2010's | 18 (16.22) | 24.3611 |
| 2020's | 4 (3.60) | 2.80 |
| Authors | Studies |
|---|---|
| Palit, P | 1 |
| Paira, P | 1 |
| Hazra, A | 1 |
| Banerjee, S | 1 |
| Gupta, AD | 1 |
| Dastidar, SG | 1 |
| Mondal, NB | 1 |
| Sunduru, N | 1 |
| Palne, S | 1 |
| Chauhan, PM | 1 |
| Gupta, S | 1 |
| Wang, MZ | 1 |
| Zhu, X | 1 |
| Srivastava, A | 1 |
| Liu, Q | 1 |
| Sweat, JM | 1 |
| Pandharkar, T | 1 |
| Stephens, CE | 1 |
| Riccio, E | 1 |
| Parman, T | 1 |
| Munde, M | 1 |
| Mandal, S | 1 |
| Madhubala, R | 1 |
| Tidwell, RR | 1 |
| Wilson, WD | 2 |
| Boykin, DW | 1 |
| Hall, JE | 1 |
| Kyle, DE | 1 |
| Werbovetz, KA | 2 |
| Caminos, AP | 1 |
| Panozzo-Zenere, EA | 1 |
| Wilkinson, SR | 1 |
| Tekwani, BL | 2 |
| Labadie, GR | 1 |
| Bharate, SB | 1 |
| Bharate, JB | 1 |
| Khan, SI | 1 |
| Jacob, MR | 1 |
| Mudududdla, R | 1 |
| Yadav, RR | 1 |
| Singh, B | 2 |
| Sharma, PR | 1 |
| Maity, S | 1 |
| Khan, IA | 1 |
| Vishwakarma, RA | 1 |
| de Morais, SM | 1 |
| Vila-Nova, NS | 1 |
| Bevilaqua, CM | 1 |
| Rondon, FC | 1 |
| Lobo, CH | 1 |
| de Alencar Araripe Noronha Moura, A | 1 |
| Sales, AD | 1 |
| Rodrigues, AP | 1 |
| de Figuereido, JR | 1 |
| Campello, CC | 1 |
| Wilson, ME | 1 |
| de Andrade, HF | 1 |
| Bosc, D | 1 |
| Mouray, E | 1 |
| Cojean, S | 1 |
| Franco, CH | 1 |
| Loiseau, PM | 3 |
| Freitas-Junior, LH | 1 |
| Moraes, CB | 1 |
| Grellier, P | 1 |
| Dubois, J | 1 |
| Jagu, E | 1 |
| Pomel, S | 1 |
| Diez-Martinez, A | 1 |
| Ramiandrasoa, F | 1 |
| Krauth-Siegel, RL | 1 |
| Pethe, S | 1 |
| Blonski, C | 1 |
| Labruère, R | 1 |
| Bhambra, AS | 1 |
| Ruparelia, KC | 1 |
| Tan, HL | 1 |
| Tasdemir, D | 1 |
| Burrell-Saward, H | 1 |
| Yardley, V | 1 |
| Beresford, KJM | 1 |
| Arroo, RRJ | 1 |
| Abdelhameed, A | 1 |
| Liao, X | 1 |
| McElroy, CA | 1 |
| Joice, AC | 1 |
| Rakotondraibe, L | 1 |
| Li, J | 1 |
| Slebodnick, C | 1 |
| Guo, P | 1 |
| Chechi, F | 1 |
| Corsi, P | 1 |
| Bartolozzi, D | 1 |
| Gaiera, G | 1 |
| Bartoloni, A | 2 |
| Zammarchi, L | 2 |
| Vechi, HT | 1 |
| Sousa, ASV | 1 |
| Cunha, MAD | 1 |
| Shaw, JJ | 1 |
| Luz, KG | 1 |
| Piccica, M | 1 |
| Lagi, F | 1 |
| Fox-Lewis, A | 1 |
| Lockwood, DNJ | 1 |
| Diro, E | 4 |
| Ritmeijer, K | 4 |
| Boelaert, M | 2 |
| Alves, F | 3 |
| Mohammed, R | 3 |
| Abongomera, C | 3 |
| Ravinetto, R | 2 |
| De Crop, M | 2 |
| Fikre, H | 4 |
| Adera, C | 2 |
| van Loen, H | 2 |
| Tsoumanis, A | 1 |
| Adriaensen, W | 2 |
| Hailu, A | 3 |
| Griensven, JV | 1 |
| Vogt, F | 1 |
| Mengesha, B | 1 |
| Asmamaw, H | 1 |
| Mekonnen, T | 1 |
| Takele, Y | 1 |
| Adem, E | 1 |
| Melsew, Y | 1 |
| van Griensven, J | 3 |
| Edwards, T | 1 |
| Kibret, A | 1 |
| Bardonneau, C | 1 |
| Soipei, P | 1 |
| Mutinda, B | 1 |
| Omollo, R | 1 |
| Zijlstra, EE | 1 |
| Wasunna, M | 1 |
| Alvar, J | 2 |
| Alexander, N | 1 |
| Blesson, S | 1 |
| Khademvatan, S | 1 |
| Eskandari, K | 1 |
| Hazrati-Tappeh, K | 1 |
| Rahim, F | 1 |
| Foroutan, M | 1 |
| Yousefi, E | 1 |
| Asadi, N | 1 |
| Villamil-Gómez, WE | 1 |
| Calderón-Gomezcaseres, Á | 1 |
| Rodriguez-Morales, AJ | 1 |
| Colebunders, R | 1 |
| Menten, J | 1 |
| Lynen, L | 1 |
| Faucher, JF | 1 |
| Morquin, D | 1 |
| Reynes, J | 1 |
| Chirouze, C | 1 |
| Hoen, B | 1 |
| Le Moing, V | 1 |
| García-Lázaro, M | 1 |
| Villar, C | 1 |
| Natera, C | 1 |
| Rivero, A | 2 |
| Patel, TA | 1 |
| Lockwood, DN | 1 |
| Rybniker, J | 1 |
| Goede, V | 1 |
| Mertens, J | 1 |
| Ortmann, M | 1 |
| Kulas, W | 1 |
| Kochanek, M | 1 |
| Benzing, T | 1 |
| Arribas, JR | 1 |
| Fätkenheuer, G | 1 |
| Reimão, JQ | 1 |
| Tempone, AG | 1 |
| De Paula, EE | 1 |
| De Sousa, FB | 1 |
| Da Silva, JC | 1 |
| Fernandes, FR | 1 |
| Melo, MN | 1 |
| Frézard, F | 1 |
| Grazul, RM | 1 |
| Sinisterra, RD | 1 |
| Machado, FC | 1 |
| Lasri, S | 2 |
| Sahibi, H | 2 |
| Natami, A | 1 |
| Rhalem, A | 2 |
| Dasgupta, B | 1 |
| Roychoudhury, K | 1 |
| Ganguly, S | 2 |
| Kumar Sinha, P | 1 |
| Vimal, S | 1 |
| Das, P | 1 |
| Roy, S | 1 |
| BOIX BARRIOS, J | 1 |
| SANCHO PASQUAU, V | 1 |
| QUILIS MORA, J | 1 |
| SOTO, JF | 1 |
| Sundar, S | 5 |
| Kumar, A | 1 |
| Cascio, G | 1 |
| Titone, L | 1 |
| Bandyopadhyay, S | 1 |
| Sarkar, A | 1 |
| Chatterjee, M | 2 |
| López-Medrano, F | 1 |
| Costa, JR | 2 |
| Rodriguez-Peralto, JL | 1 |
| Aguado, JM | 1 |
| Antinori, S | 1 |
| Longhi, E | 1 |
| Bestetti, G | 1 |
| Piolini, R | 1 |
| Acquaviva, V | 1 |
| Foschi, A | 1 |
| Trovati, S | 1 |
| Parravicini, C | 1 |
| Corbellino, M | 1 |
| Meroni, L | 1 |
| HAZARIKA, AN | 1 |
| Manfredi, R | 1 |
| Marinacci, G | 1 |
| Calza, L | 1 |
| Passarini, B | 1 |
| Thakur, CP | 7 |
| Wali, JP | 2 |
| Sharma, SK | 1 |
| Guleria, JS | 1 |
| Keithly, JS | 1 |
| Langreth, SG | 1 |
| Jha, TK | 3 |
| Sharma, VK | 1 |
| Ballin, A | 1 |
| Theodor, R | 1 |
| Boichis, H | 1 |
| Rotem, Y | 1 |
| Altman, G | 1 |
| Wittermann, C | 1 |
| Reindke, B | 1 |
| Bienzle, U | 1 |
| Nyakundi, PM | 1 |
| Rashid, JR | 1 |
| Wasunna, KM | 1 |
| Were, JB | 2 |
| Muigai, R | 2 |
| Kirigi, G | 1 |
| Mbugua, J | 1 |
| Lustig, V | 1 |
| Kager, PA | 2 |
| Meenhorst, PL | 1 |
| Mehrotra, R | 1 |
| Choudhry, VP | 1 |
| Saxena, R | 1 |
| Kapila, K | 1 |
| Saraya, AK | 1 |
| Fusai, T | 3 |
| Durand, R | 5 |
| Boulard, Y | 2 |
| Paul, M | 5 |
| Bories, C | 3 |
| Rivollet, D | 5 |
| Houin, R | 5 |
| Deniau, M | 5 |
| Rodilla, F | 1 |
| Magraner, J | 1 |
| Aznar, J | 1 |
| Orovitg, F | 1 |
| Alcácer, F | 1 |
| Colomina, J | 1 |
| Ferriols, F | 1 |
| Bichile, LS | 1 |
| Giri, OP | 1 |
| Chandra, J | 1 |
| Patwari, AK | 1 |
| Laguna, F | 2 |
| García-Samaniego, J | 1 |
| Soriano, V | 2 |
| Valencia, E | 1 |
| Redondo, C | 1 |
| Alonso, MJ | 1 |
| González-Lahoz, JM | 2 |
| Rosenkaimer, F | 1 |
| Murray, HW | 2 |
| Bouree, P | 2 |
| Belec, L | 1 |
| Kar, S | 1 |
| Kar, K | 1 |
| Bhattacharya, PK | 1 |
| Ghosh, DK | 2 |
| Hariprashad, J | 1 |
| Fichtl, RE | 1 |
| Mauny, I | 1 |
| Blanchot, I | 1 |
| Degeilh, B | 1 |
| Dabadie, A | 1 |
| Guiguen, C | 1 |
| Roussey, M | 1 |
| Singh, S | 2 |
| Gilman-Sachs, A | 1 |
| Chang, KP | 1 |
| Reed, SG | 1 |
| Ozsoylu, S | 1 |
| Mishra, M | 2 |
| Piarroux, R | 1 |
| Garnier, JM | 1 |
| Gambarelli, F | 1 |
| Dumon, H | 1 |
| Kaplanski, S | 1 |
| Unal, D | 1 |
| Pérez-Molina, JA | 2 |
| López-Vélez, R | 1 |
| Montilla, P | 1 |
| Guerrero, A | 2 |
| Banerjee, G | 1 |
| Nandi, G | 1 |
| Mahato, SB | 1 |
| Pakrashi, A | 1 |
| Basu, MK | 1 |
| Astier, A | 4 |
| Jha, BB | 1 |
| Abraham, G | 1 |
| Leo, YS | 1 |
| Singh, M | 1 |
| Wong, SY | 1 |
| Adrados, M | 1 |
| Valencia, ME | 1 |
| Moreno, V | 1 |
| Polo, R | 1 |
| Verdejo, J | 1 |
| Jiménez, MI | 1 |
| Martínez, P | 1 |
| Martínez, ML | 1 |
| Fessi, H | 1 |
| Mesa-Valle, CM | 1 |
| Rodriguez-Cabezas, MN | 1 |
| Moraleda-Lindez, V | 1 |
| Craciunescu, D | 1 |
| Sanchez-Moreno, M | 1 |
| Osuna, A | 1 |
| Mbongo, N | 1 |
| Craciunescu, DG | 1 |
| Robert-Gero, M | 1 |
| Jaffe, CL | 1 |
| Hamerlinck, FF | 1 |
| van Gool, T | 1 |
| Faber, WR | 1 |
| Kumar, J | 1 |
| Singh, R | 1 |
| Dwivedi, SN | 1 |
| Das, VN | 1 |
| Ranjan, A | 1 |
| Sinha, AN | 1 |
| Verma, N | 1 |
| Lal, CS | 1 |
| Gupta, AK | 2 |
| Siddiqui, NA | 1 |
| Kar, SK | 1 |
| Lichey, J | 1 |
| Linderer, T | 1 |
| Dissmann, T | 1 |
| Raether, W | 1 |
| Seidenath, H | 1 |
| Loewe, H | 1 |
| Kapur, MR | 1 |
| Chopra, SK | 1 |
| Hasan, MI | 1 |
| Sinha, KP | 1 |
| Kumar, SC | 1 |
| Haarscher, A | 1 |
| Gardéa, A | 1 |
| de Benoist, B | 1 |
| Kien, T | 1 |
| Rohmer, A | 1 |
| Lafeuillade, A | 1 |
| Chaffanjon, P | 1 |
| Delbeke, E | 1 |
| Quilichini, R | 1 |
| Sodhi, S | 1 |
| Kaur, S | 1 |
| Mahajan, RC | 1 |
| Ganguly, NK | 1 |
| Malla, N | 1 |
| Kumar, M | 3 |
| Mattot, M | 1 |
| Ninane, J | 1 |
| Bigaignon, G | 1 |
| Vermylen, C | 1 |
| Cornu, G | 1 |
| Biswas, UK | 1 |
| Jha, DN | 1 |
| Khan, AB | 1 |
| Medrano, FJ | 1 |
| Hernández-Quero, J | 1 |
| Jiménez, E | 1 |
| Pineda, JA | 1 |
| Sánchez-Quijano, A | 1 |
| Velez, ID | 1 |
| Viciana, P | 1 |
| Castillo, R | 1 |
| Reyes, MJ | 1 |
| Mehabresh, MI | 1 |
| el-Mauhoub, MM | 1 |
| Matheron, S | 1 |
| Cabié, A | 1 |
| Parquin, F | 1 |
| Mayaud, C | 1 |
| Roux, P | 1 |
| Antoine, M | 1 |
| Chougnet, C | 1 |
| Coulaud, JP | 1 |
| Aggarwal, P | 1 |
| Gupta, U | 1 |
| Saluja, S | 1 |
| Pandey, AK | 2 |
| Mikou, N | 1 |
| Balafrej, A | 1 |
| Benhamou, B | 1 |
| Mikou, S | 1 |
| Baroudi, A | 1 |
| Fenske, S | 1 |
| Stellbrink, HJ | 1 |
| Albrecht, H | 1 |
| Greten, H | 1 |
| del Mar Sanz, M | 1 |
| Rubio, R | 1 |
| Casillas, A | 1 |
| Guijarro, C | 1 |
| Martinez, R | 1 |
| de Dios Garcia, J | 1 |
| Morin, D | 1 |
| Dumas, ML | 1 |
| Valette, H | 1 |
| Dumas, R | 1 |
| Jha, SN | 1 |
| Singh, NK | 1 |
| Bhattacharya, D | 1 |
| Majhi, TK | 1 |
| Dutta, RK | 1 |
| Anciaux, ML | 1 |
| Taugourdeau, P | 1 |
| Bryceson, AD | 1 |
| Chulay, JD | 1 |
| Mugambi, M | 1 |
| Gachihi, G | 1 |
| Chunge, CN | 1 |
| Bhatt, SM | 1 |
| Ho, M | 1 |
| Spencer, HC | 1 |
| Tsetentis, Y | 1 |
| Pippard, MJ | 1 |
| Moir, D | 1 |
| Weatherall, DJ | 1 |
| Lenicker, HM | 1 |
| Pujol, M | 1 |
| Carratala, J | 1 |
| Mauri, J | 1 |
| Viladrich, PF | 1 |
| Berman, JD | 1 |
| Gallalee, JV | 1 |
| Williams, JS | 1 |
| Hockmeyer, WD | 1 |
| Ghosh, AK | 1 |
| Bhattacharyya, FK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study[NCT01360762] | Phase 3 | 74 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine.[NCT02011958] | Phase 3 | 59 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with SAEs which are possibly, probably or definitely drug-related following clinician's assessment or that lead to permanent drug discontinuations during the first year of pentamidine administration (NCT01360762)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentamidine Secondary Prophylaxis (PSP) | 3 |
During the first year of pentamidine administration for prophylaxis: participants with any drug-related non-serious adverse events (with drug-related defined as possibly, probably or definitely related to primary therapy following physicians assessment) as well as any serious adverse events (drug-related or not) (NCT01360762)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Drug-related non-serious adverse events | Any serious adverse event | |
| Pentamidine Secondary Prophylaxis (PSP) | 30 | 17 |
The number of required additional clinical interventions/therapeutic procedures (NCT01360762)
Timeframe: 30 months
| Intervention | number of events (Number) | |||
|---|---|---|---|---|
| Additional IV fluid during PM administration | Prolonged hospital observation | additional medication during PM infusion | Additional IV or oral glucose | |
| Pentamidine Secondary Prophylaxis (PSP) | 10 | 2 | 2 | 1 |
Number of treatment discontinuations and interruptions/missed doses. (NCT01360762)
Timeframe: 30 months
| Intervention | number of events (Number) | ||
|---|---|---|---|
| Permanent discontinuation | Missed more than 1 dose | Treatment interruption | |
| Pentamidine Secondary Prophylaxis (PSP) | 2 | 4 | 0 |
Probability of relapse-free survival up to one year after the start of the intervention (PSP) (at month 6 and month 12) (NCT01360762)
Timeframe: up to 1 year after the start of the intervention (PSP)
| Intervention | percentage probability (Number) | |
|---|---|---|
| Probability of relapse-free survival at 6 months | Probability of relapse-free survival at 12 months | |
| Pentamidine Secondary Prophylaxis (PSP) | 79 | 71 |
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
11 reviews available for pentamidine and Leishmaniasis, Visceral
| Article | Year |
|---|---|
Efficacy and safety of pentamidine isethionate for tegumentary and visceral human leishmaniasis: a systematic review.
Topics: Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Leishmaniasis, | 2021 |
Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure--a case report and brief review of the literature.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Drug Therapy, Com | 2010 |
Visceral leishmaniasis - current therapeutic modalities.
Topics: Administration, Oral; Amphotericin B; Animals; Antimony Sodium Gluconate; Antineoplastic Agents; Ant | 2006 |
Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Americas; Antiprotozoal Agents; Antiretroviral Therapy, Highly A | 2007 |
[Importance of drug carriers in the treatment of visceral leishmaniasis].
Topics: Amphotericin B; Drug Carriers; Drug Resistance; Humans; Leishmaniasis, Visceral; Liposomes; Pentamid | 1995 |
Anti leishmanial therapy--the changing scene.
Topics: Allopurinol; Amphotericin B; Antimony Sodium Gluconate; Humans; Leishmaniasis, Visceral; Pentamidine | 1994 |
Diagnosis and treatment of kala-azar.
Topics: Allopurinol; Amphotericin B; Antimony Sodium Gluconate; Child; Combined Modality Therapy; Humans; Ke | 1994 |
Gastrointestinal leishmaniasis in human immunodeficiency virus-infected patients: report of five cases and review.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Animals; Antimony; | 1994 |
Leishmaniasis: report of 33 cases and a review of the literature.
Topics: Allopurinol; Animals; Child, Preschool; Disease Reservoirs; Female; Global Health; Humans; Leishmani | 1993 |
Treatment of visceral leishmaniasis.
Topics: Administration, Oral; Amphotericin B; Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Paromom | 2001 |
Treatment for visceral leishmaniasis.
Topics: Allopurinol; Amidines; Animals; Antimony Sodium Gluconate; Gluconates; Glycolysis; Leishmania; Leish | 1987 |
9 trials available for pentamidine and Leishmaniasis, Visceral
| Article | Year |
|---|---|
Long-term Clinical Outcomes in Visceral Leishmaniasis/Human Immunodeficiency Virus-Coinfected Patients During and After Pentamidine Secondary Prophylaxis in Ethiopia: A Single-Arm Clinical Trial.
Topics: Adult; Antiprotozoal Agents; Coinfection; Ethiopia; Female; HIV Infections; Humans; Leishmaniasis, V | 2018 |
Antigen Detection in Urine for Noninvasive Diagnosis and Treatment Monitoring of Visceral Leishmaniasis in Human Immunodeficiency Virus Coinfected Patients: An Exploratory Analysis from Ethiopia.
Topics: Adult; Antigens, Protozoan; Antiprotozoal Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphoc | 2018 |
Treatment of visceral Leishmaniasis unresponsive to pentamidine with amphotericin B.
Topics: Adolescent; Adult; Amphotericin B; Drug Resistance; Female; Humans; Leishmaniasis, Visceral; Male; M | 1994 |
A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis.
Topics: Adolescent; Allopurinol; Antiprotozoal Agents; Chi-Square Distribution; Child; Drug Therapy, Combina | 2001 |
Observations on the effect of verapamil with sodium stibogluconate in kala azar.
Topics: Administration, Oral; Adult; Antimony Sodium Gluconate; Drug Resistance; Drug Therapy, Combination; | 1992 |
Amphotericin versus pentamidine in antimony-unresponsive kala-azar.
Topics: Adult; Amphotericin B; Antimony Sodium Gluconate; Female; Humans; Leishmaniasis, Visceral; Male; Pen | 1992 |
Evaluation of efficacy of longer durations of therapy of fresh cases of kala-azar with sodium stibogluconate.
Topics: Adult; Antimony Sodium Gluconate; Child; Female; Follow-Up Studies; Humans; Leishmaniasis, Visceral; | 1991 |
Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study.
Topics: Adolescent; Adult; Antimony Sodium Gluconate; Child; Child, Preschool; Drug Administration Schedule; | 1991 |
Treatment of visceral leishmaniasis in Bihar.
Topics: Amidines; Antimony Sodium Gluconate; Clinical Trials as Topic; Gluconates; Humans; India; Leishmania | 1986 |
91 other studies available for pentamidine and Leishmaniasis, Visceral
| Article | Year |
|---|---|
Phase transfer catalyzed synthesis of bis-quinolines: antileishmanial activity in experimental visceral leishmaniasis and in vitro antibacterial evaluation.
Topics: Animals; Anti-Bacterial Agents; Antiprotozoal Agents; Catalysis; Leishmania donovani; Leishmaniasis, | 2009 |
Synthesis and antileishmanial activity of novel 2,4,6-trisubstituted pyrimidines and 1,3,5-triazines.
Topics: Animals; Antiprotozoal Agents; Cricetinae; Dose-Response Relationship, Drug; Drug Design; Leishmania | 2009 |
Novel arylimidamides for treatment of visceral leishmaniasis.
Topics: Amidines; Animals; Antiprotozoal Agents; Biological Availability; Cricetinae; Disease Models, Animal | 2010 |
Synthesis and antikinetoplastid activity of a series of N,N'-substituted diamines.
Topics: Animals; Antiprotozoal Agents; Chagas Disease; Diamines; Humans; Inhibitory Concentration 50; Kineto | 2012 |
Discovery of 3,3'-diindolylmethanes as potent antileishmanial agents.
Topics: Antiprotozoal Agents; Drug Discovery; Humans; Indoles; Inhibitory Concentration 50; Leishmania donov | 2013 |
Thymol and eugenol derivatives as potential antileishmanial agents.
Topics: Animals; Antiprotozoal Agents; Cell Line; Eugenol; Humans; Leishmania infantum; Leishmaniasis, Visce | 2014 |
Highly improved antiparasitic activity after introduction of an N-benzylimidazole moiety on protein farnesyltransferase inhibitors.
Topics: Alkyl and Aryl Transferases; Animals; Antiparasitic Agents; Cell Line; Enzyme Inhibitors; Humans; Im | 2016 |
Synthesis and in vitro antikinetoplastid activity of polyamine-hydroxybenzotriazole conjugates.
Topics: Animals; Antiprotozoal Agents; Humans; Leishmania donovani; Leishmaniasis, Visceral; NADH, NADPH Oxi | 2017 |
Synthesis and antitrypanosomal activities of novel pyridylchalcones.
Topics: Animals; Cells, Cultured; Chagas Disease; Chalcones; Humans; Leishmania donovani; Leishmaniasis, Vis | 2017 |
Synthesis and antileishmanial evaluation of thiazole orange analogs.
Topics: Animals; Benzothiazoles; Drug Discovery; Leishmaniasis, Visceral; Quinolines | 2020 |
Case Report: Intravenous Pentamidine Rescue Treatment for Active Chronic Visceral Leishmaniasis in an HIV-1 Infected Patient.
Topics: Administration, Intravenous; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Coinfectio | 2021 |
Case Report: Combination Therapy with Liposomal Amphotericin B, N-Methyl Meglumine Antimoniate, and Pentamidine Isethionate for Disseminated Visceral Leishmaniasis in a Splenectomized Adult Patient.
Topics: Amphotericin B; Antiprotozoal Agents; Bone Marrow; Drug Therapy, Combination; Humans; Immunocompromi | 2020 |
Visceral leishmaniasis complicating idiopathic CD4+ T-cell lymphocytopenia: 2 case reports.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Male; Middle Aged; Pen | 2017 |
Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia.
Topics: Adult; Antiprotozoal Agents; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Ethiopia; Female; HI | 2019 |
In silico and in vitro comparative activity of green tea components against Leishmania infantum.
Topics: Amide Synthases; Antioxidants; Arginase; Catechin; Cell Proliferation; Computer Simulation; Iran; Le | 2019 |
Visceral leishmaniasis in a patient with systemic lupus erythematosus from Colombia, Latin America.
Topics: Adult; Antiprotozoal Agents; Colombia; Humans; Leishmaniasis, Visceral; Lupus Erythematosus, Systemi | 2019 |
Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Cohort Studies; Female; Humans; | 2015 |
Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection.
Topics: Antiprotozoal Agents; Coinfection; HIV Infections; Humans; Immunocompromised Host; Leishmania infant | 2016 |
[Raised tattoos in a human-immunodeficiency-virus-infected patient].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiprotozoal Agents; Antiretroviral | 2009 |
Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; CD4-Positive T-Lymphocytes; HIV- | 2009 |
Investigation into in vitro anti-leishmanial combinations of calcium channel blockers and current anti-leishmanial drugs.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Calcium Channel Blockers; Cricetinae; Drug Therapy, C | 2011 |
Insights into the multi-equilibrium, superstructure system based on β-cyclodextrin and a highly water soluble guest.
Topics: Animals; Antiprotozoal Agents; beta-Cyclodextrins; Female; Leishmania infantum; Leishmaniasis, Visce | 2012 |
Western blot analysis of Leishmania infantum antigens using sera from pentamidine-treated dogs.
Topics: Animals; Antibodies, Protozoan; Antigens, Protozoan; Blotting, Western; Dog Diseases; Dogs; Leishman | 2003 |
Antileishmanial drugs cause up-regulation of interferon-gamma receptor 1, not only in the monocytes of visceral leishmaniasis cases but also in cultured THP1 cells.
Topics: Acute Disease; Adolescent; Adult; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Blotting | 2003 |
[Treatment of kala-azar with diamidine].
Topics: Amidines; Humans; Leishmaniasis; Leishmaniasis, Visceral; Pentamidine | 1950 |
Challenges in the management of visceral leishmaniasis.
Topics: Amebicides; Amphotericin B; Antimony Sodium Gluconate; Antiparasitic Agents; Antiprotozoal Agents; E | 2005 |
Visceral leishmaniasis therapy.
Topics: Antimony; Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Pentamidine | 1989 |
Development of a semi-automated colorimetric assay for screening anti-leishmanial agents.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Colorimetry; Drug Evaluation, Preclinical; Humans; In | 2006 |
An HIV-positive man with tattoo induration.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Animals; Antiprotozoal Agents; Biopsy, Needle | 2007 |
Treatment of kala-azar with pentamidine isothionate; a study of 55 cases.
Topics: Humans; Leishmaniasis; Leishmaniasis, Visceral; Pentamidine | 1949 |
Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine a
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Drug Carriers; HIV Infections; Humans; Leishmaniasis, V | 2008 |
Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis).
Topics: Adolescent; Adult; Antimony Sodium Gluconate; Child; Child, Preschool; Disease Outbreaks; Female; Hu | 1984 |
Treatment of visceral leishmaniasis.
Topics: Allopurinol; Antimony Sodium Gluconate; Humans; Leishmaniasis, Visceral; Pentamidine | 1984 |
Inefficacy of metronidazole in experimental infections of Leishmania donovani, L. mexicana, and Trypanosoma brucei brucei.
Topics: Animals; Antimony Sodium Gluconate; Cricetinae; Leishmaniasis; Leishmaniasis, Visceral; Mesocricetus | 1983 |
Pentamidine-induced diabetes mellitus.
Topics: Amidines; Diabetes Mellitus; Diabetes Mellitus, Type 1; Humans; Leishmaniasis, Visceral; Pentamidine | 1984 |
Evaluation of diamidine compound (pentamidine isethionate) in the treatment resistant cases of kala-azar occurring in North Bihar, India.
Topics: Adult; Amidines; Child, Preschool; Diabetes Mellitus; Drug Resistance, Microbial; Female; Heart Dise | 1983 |
[Kala-azar in childhood].
Topics: Antimony; Antiprotozoal Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; | 1980 |
[Diagnosis and therapy of visceral leishmaniasis].
Topics: Antimony; Child, Preschool; Humans; Leishmaniasis, Visceral; Pentamidine; Recurrence | 1980 |
Problems in the treatment of kala-azar: case report.
Topics: Allopurinol; Animals; Antimetabolites; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Human | 1995 |
Treatment of visceral leishmaniasis in a patient with AIDS with antimony and gamma-interferon: remission and prevention of relapse by maintenance therapy with weekly pentamidine.
Topics: Adult; AIDS-Related Opportunistic Infections; Antimony; Antiprotozoal Agents; Drug Administration Sc | 1995 |
Asymptomatic visceral leishmaniasis in a child with acute lymphoblastic leukaemia.
Topics: Antimony Sodium Gluconate; Child, Preschool; Humans; India; Leishmaniasis, Visceral; Male; Pentamidi | 1995 |
Amphotericin B for visceral leishmaniasis resistant to pentavalent antimonial drugs in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amphotericin B; Antimony; Antiprotozoal Agents; Drug Resi | 1994 |
Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma.
Topics: Adolescent; Adult; Antimony Sodium Gluconate; Child; Combined Modality Therapy; Death; Drug Administ | 1994 |
Experimental visceral leishmaniasis: role of trans-aconitic acid in combined chemotherapy.
Topics: Aconitic Acid; Allopurinol; Animals; Antimony Sodium Gluconate; Cells, Cultured; Cricetinae; Drug Th | 1993 |
Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine.
Topics: Amphotericin B; Animals; Disease Models, Animal; Female; Immunocompromised Host; Immunosuppression T | 1993 |
[Visceral leishmaniasis in an infant in Brittany: discussion on the modes of transmission out endemic zones].
Topics: France; Humans; Infant; Leishmaniasis, Visceral; Male; Meglumine; Pentamidine; Transfusion Reaction | 1993 |
Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis.
Topics: Adolescent; Adult; Antigens, Protozoan; Antimony Sodium Gluconate; Child; Child, Preschool; Enzyme-L | 1995 |
Treatment of kala azar.
Topics: Antimony; Antiprotozoal Agents; Drug Therapy, Combination; Humans; Leishmaniasis, Visceral; Meglumin | 1996 |
Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B.
Topics: Amphotericin B; Anti-Bacterial Agents; Antiprotozoal Agents; Drug Administration Schedule; Humans; L | 1995 |
[Resistance of Leishmania infantum to Glucantime: risk factors and therapeutic management].
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Female; Humans; Immunity, Cellular; Infant; Interfer | 1996 |
Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients.
Topics: AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Pentam | 1996 |
Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Antiprotozoal Agents; Cricetinae; Drug Delivery | 1996 |
Action of pentamidine-bound nanoparticles against Leishmania on an in vivo model.
Topics: Animals; Antimony; Antiprotozoal Agents; Colloids; Disease Models, Animal; Drug Carriers; Female; Le | 1994 |
Amphotericin B in visceral leishmaniasis.
Topics: Amphotericin B; Anti-Bacterial Agents; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Resista | 1996 |
Secondary prophylaxis for visceral leishmaniasis in HIV-infected individuals.
Topics: AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Pentam | 1997 |
Ultrastructural changes in parasites induced by nanoparticle-bound pentamidine in a Leishmania major/mouse model.
Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Carriers; Kupffer Cells; Leishmania majo | 1997 |
Activity of pentamidine-loaded methacrylate nanoparticles against Leishmania infantum in a mouse model.
Topics: Animals; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Leishmania infantum; Lei | 1997 |
A case report of visceral leishmaniasis in Singapore.
Topics: Adult; Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Male; Pentamidine; Singapore | 1997 |
Visceral leishmaniasis in patients infected with the human immunodeficiency virus.
Topics: AIDS-Related Opportunistic Infections; Allopurinol; Amebicides; Amphotericin B; Analysis of Variance | 1997 |
Activity of pentamidine-loaded poly (D,L-lactide) nanoparticles against Leishmania infantum in a murine model.
Topics: Animals; Antiprotozoal Agents; Delayed-Action Preparations; Disease Models, Animal; Dose-Response Re | 1997 |
In vitro and in vivo activity of two Pt(IV) salts against leishmania donovani.
Topics: Animals; Antiprotozoal Agents; Cell Line; Cricetinae; Drug Evaluation, Preclinical; Humans; Leishman | 1998 |
Synergistic effect of Ir-(COT)-pentamidine alizarin red and pentamidine, amphotericin B, and paromomycin on Leishmania donovani.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Synergism; Female; Iridium; Leishmania donovani; | 1998 |
Analysis of immune responses in dogs with canine visceral leishmaniasis before, and after, drug treatment.
Topics: Animals; Antibodies, Protozoan; Antigens, Protozoan; Dog Diseases; Dogs; Enzyme-Linked Immunosorbent | 1999 |
Serum neopterin concentrations during treatment of leishmaniasis: useful as test of cure?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents | 2000 |
Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable anti-leishmanial drugs: a community-based study.
Topics: Adolescent; Adult; Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Equipment | 2000 |
Drug resistance in Indian visceral leishmaniasis.
Topics: Aminoquinolines; Amphotericin B; Antimony; Antiprotozoal Agents; Dose-Response Relationship, Drug; D | 2001 |
[A case of visceral leishmaniasis (Kala-Azar). Side effects during the treatment with pentamidine].
Topics: Adult; Alanine Transaminase; Amidines; Aspartate Aminotransferases; Blood Glucose; Creatinine; Human | 1979 |
Action of p-(4-amidino-phenoxy)-benzaldehyde-p-amidino-phenylhydrazone dihydrochloride on Leishmania donovani infections in the golden hamster.
Topics: Amidines; Animals; Antimony; Antimony Sodium Gluconate; Cricetinae; Drug Evaluation, Preclinical; Le | 1978 |
Kala-azar in North Western Uttar Pradesh.
Topics: Adult; Bone Marrow Examination; Child; Female; Humans; India; Leishmaniasis, Visceral; Male; Middle | 1979 |
Study of the outbreak of kala-azar epidemic in Bihar.
Topics: Adolescent; Adult; Antimony; Child; Child, Preschool; Disease Outbreaks; Female; Humans; India; Infa | 1978 |
[Visceral leishmaniasis in 2 siblings and their father].
Topics: Adult; Antimony; Child; Female; France; Humans; Leishmaniasis, Visceral; Male; Meglumine; Pentamidin | 1978 |
Maintenance itraconazole for visceral leishmaniasis in HIV infection.
Topics: Adult; Antifungal Agents; Female; HIV Infections; Humans; Itraconazole; Ketoconazole; Leishmaniasis, | 1992 |
Effect of sodium stibogluconate and pentamidine on in vitro multiplication of Leishmania donovani in peritoneal macrophages from infected and drug-treated BALB/c mice.
Topics: Animals; Antimony Sodium Gluconate; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Mice; | 1992 |
Visceral and cutaneous leishmaniasis in an European paediatric population.
Topics: Animals; Antiprotozoal Agents; Bone Marrow; Child; Child, Preschool; Drug Therapy, Combination; Fema | 1992 |
Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain?
Topics: Adult; AIDS-Related Opportunistic Infections; Allopurinol; Antiprotozoal Agents; CD4-Positive T-Lymp | 1992 |
Visceral leishmaniasis in Libya--review of 21 cases.
Topics: Antimony Sodium Gluconate; Bronchopneumonia; Child, Preschool; Humans; Infant; Leishmaniasis, Viscer | 1992 |
Visceral leishmaniasis and HIV infection: unusual presentation with pleuropulmonary involvement, and effect of secondary prophylaxis.
Topics: HIV Infections; Humans; Leishmaniasis, Visceral; Lung Diseases, Parasitic; Male; Middle Aged; Opport | 1992 |
Ketoconazole in the treatment of antimony- and pentamidine-resistant kala-azar.
Topics: Antimony; Drug Resistance; Humans; Ketoconazole; Leishmaniasis, Visceral; Pentamidine | 1992 |
[Infantile visceral leishmaniasis in Morocco. A review of 67 cases managed at the Rabat Hospital for children (1979-1988)].
Topics: Adolescent; Age Factors; Antimony Sodium Gluconate; Bone Marrow Examination; Child; Child, Preschool | 1991 |
Visceral leishmaniasis in an HIV-infected patient: clinical features and response to treatment.
Topics: Adult; AIDS Serodiagnosis; Antimony Sodium Gluconate; CD4-CD8 Ratio; HIV Infections; HIV-1; Humans; | 1991 |
Visceral leishmaniasis in HIV-infected patients.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Female; HIV Infections; Humans; Leishmaniasis, Visceral | 1991 |
[Transitory acute kidney insufficiency and insulin-dependent after treatment of kala-azar with pentamidine and N-methylglucamine antimony].
Topics: Acute Kidney Injury; Antimony; Antiprotozoal Agents; Child, Preschool; Diabetes Mellitus, Type 1; Hu | 1991 |
Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial.
Topics: Adult; Drug Evaluation; Female; Follow-Up Studies; Humans; Leishmaniasis, Visceral; Male; Pentamidin | 1991 |
Kala-azar: unresponsiveness to prolonged sodium stibogluconate therapy.
Topics: Adolescent; Adult; Antimony Sodium Gluconate; Drug Resistance; Female; Gluconates; Humans; Leishmani | 1987 |
[Methylglucamine antimoniate and sodium stibogluconate in the treatment of leishmaniasis. Study of 16 cases].
Topics: Adolescent; Adult; Antimony; Antimony Sodium Gluconate; Child; Child, Preschool; Female; Gluconates; | 1985 |
Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine.
Topics: Amidines; Antimony Sodium Gluconate; Child; Drug Resistance; Female; Gluconates; Humans; Leishmanias | 1985 |
[Treatment of visceral leishmaniasis].
Topics: Animals; Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Resistance, Microbial; Huma | 1985 |
Mechanism of anaemia in resistant visceral leishmaniasis.
Topics: Anemia; Antimony Sodium Gluconate; Erythrocyte Aging; Erythropoiesis; Female; Ferritins; Humans; Inf | 1986 |
Ventricular tachycardia due to pentamidine isethionate.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amidines; Humans; Leishmaniasis, Visceral; Male; Pentamid | 1988 |
Activity of pentamidine-containing human red cell ghosts against visceral leishmaniasis in the hamster.
Topics: Amidines; Animals; Cricetinae; Dose-Response Relationship, Drug; Erythrocyte Membrane; Humans; Leish | 1986 |
Leishmania donovani: amastigote inhibition and mode of action of berberine.
Topics: Animals; Berberine; Berberine Alkaloids; Bone Marrow; Cricetinae; DNA; Energy Metabolism; Erythrocyt | 1985 |